Workflow
江中药业(600750) - 2015 Q1 - 季度财报
JZYYJZYY(SH:600750)2015-04-24 16:00

Financial Performance - Revenue decreased by 10.97% to CNY 622,532,331.98 compared to the same period last year[6] - Net profit attributable to shareholders increased by 18.63% to CNY 63,737,729.29 year-to-date[6] - Net profit attributable to shareholders after deducting non-recurring gains and losses rose by 10.01% to CNY 58,049,593.51[6] - Total revenue for Q1 2015 was ¥622,532,331.98, a decrease of 10.96% from ¥699,207,726.58 in the same period last year[26] - Net profit for Q1 2015 was ¥65,402,391.76, up 21.83% from ¥53,711,078.01 year-over-year[28] - Earnings per share increased to ¥0.21 from ¥0.17, representing a growth of 23.53%[28] - Total comprehensive income for the first quarter of 2015 was ¥74,881,615, an increase from ¥68,430,991 in the previous year, representing an increase of approximately 6.4%[31] Cash Flow - Operating cash flow net amount surged by 690.14% to CNY 92,770,984.64 year-to-date[6] - The net cash flow from operating activities for the reporting period was CNY 92.77 million, an increase of CNY 81.03 million, representing a growth rate of 690.14% compared to the same period last year[13] - Cash inflow from operating activities was ¥931,194,042, compared to ¥855,311,629 in the same period last year, indicating a growth of about 8.9%[33] - Net cash flow from operating activities reached ¥92,770,984.64, significantly up from ¥11,741,103.21 in the previous year, marking an increase of approximately 687.5%[34] - Cash inflow from operating activities for the parent company was ¥614,468,390.23, down from ¥741,224,405.90, a decrease of about 17.1%[36] - Net cash flow from operating activities for the parent company was ¥17,888,812.91, down from ¥25,627,479.06, a decline of approximately 30.3%[36] Assets and Liabilities - Total assets increased by 0.67% to CNY 3,349,323,093.22 compared to the end of the previous year[6] - Total assets as of March 31, 2015, amounted to CNY 3.35 billion, an increase from CNY 3.33 billion at the beginning of the year[19] - The total liabilities as of March 31, 2015, were CNY 1.15 billion, a decrease from CNY 1.19 billion at the beginning of the year[20] - The total equity attributable to shareholders of the parent company was CNY 2.14 billion, an increase from CNY 2.08 billion at the beginning of the year[20] - Total assets rose to ¥3,009,023,647.08, compared to ¥2,939,315,996.17, marking an increase of 2.41%[24] - Total liabilities decreased slightly to ¥732,750,378.18 from ¥737,924,342.27, a reduction of 0.23%[24] - The company's cash and cash equivalents were not explicitly detailed, but total current assets increased to ¥1,489,623,630.64 from ¥1,412,651,009.91, an increase of 5.45%[24] - The company’s total equity increased to ¥2,276,273,268.90 from ¥2,201,391,653.90, reflecting a growth of 3.4%[24] Shareholder Information - Total number of shareholders reached 17,555 at the end of the reporting period[10] - The largest shareholder, Jiangxi Jiangzhong Pharmaceutical Group, holds 43.03% of the shares, totaling 129,081,660 shares[11] Expenses and Investments - Accounts receivable increased by 56.52% to CNY 175,170,000 due to increased sales credit policy[12] - Construction in progress increased by 43.45% to CNY 32,600,000 mainly due to ongoing investment in R&D building[12] - Employee compensation payable decreased by 73.57% to CNY 20,240,000 due to performance bonuses paid[12] - The company reported a significant reduction in sales expenses, which fell to ¥186,180,777.64 from ¥253,829,611.00, a decrease of 26.59%[27] - The company maintained a stable long-term investment portfolio with long-term equity investments at ¥269,696,020.91, slightly down from ¥270,168,012.53[24] Other Financial Metrics - The impairment loss on assets for the reporting period was CNY 3.40 million, a decrease of CNY 1.82 million, with a decline rate of 34.83% due to the reversal of previously accrued bad debt provisions[13] - The ending balance of interest payable was CNY 8.91 million, an increase of CNY 7.02 million, with a growth rate of 370.88% primarily due to the accrual of bond interest during the reporting period[13] - The ending balance of other current liabilities was CNY 32.58 million, an increase of CNY 12.10 million, representing a growth rate of 59.10% mainly due to the increase in accrued but unpaid expenses during the reporting period[13] - The net cash flow from investing activities for the reporting period was CNY -53.29 million, a decrease of CNY 33.19 million, representing a decline rate of 165.17% mainly due to the issuance of entrusted loans amounting to CNY 40 million[14] - The net cash flow from financing activities for the reporting period was CNY -0.22 million, an increase of CNY 54.43 million, representing a growth rate of 96.20% compared to the same period last year[14] - Cash outflow for purchasing goods and services was ¥206,329,576.43, up from ¥132,343,120.95, reflecting a rise of about 55.8%[33] - Net cash flow from investing activities was -¥53,289,354.28, worsening from -¥20,096,525.14 in the previous year, indicating a decline of approximately 165.5%[34] - Cash and cash equivalents at the end of the period totaled ¥642,859,401.42, slightly down from ¥646,253,270.85 year-over-year[35] - Cash and cash equivalents for the parent company at the end of the period were ¥505,898,995.91, down from ¥600,863,002.30, a decrease of about 15.8%[37] - The company reported a net cash outflow from financing activities of -¥1,736,216.05, an improvement from -¥56,185,548.51 in the previous year, indicating a reduction in cash outflow by approximately 96.9%[37]